<?xml version="1.0" encoding="UTF-8"?>
<p>It has been recently estimated that 71 million people are chronically infected with HCV worldwide, including 15 million in the MENA region, which is the most affected.
 <xref rid="hep41310-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="hep41310-bib-0004" ref-type="ref">4</xref> Most of those infected, however, are unaware of their infection; infection is mostly asymptomatic until advanced stages of disease.
 <xref rid="hep41310-bib-0014" ref-type="ref">14</xref> With the breakthroughs in treatment, namely the development of highly efficacious oral direct‐acting antivirals (DAAs),
 <xref rid="hep41310-bib-0015" ref-type="ref">15</xref>, 
 <xref rid="hep41310-bib-0016" ref-type="ref">16</xref>, 
 <xref rid="hep41310-bib-0017" ref-type="ref">17</xref> and the rapid drop in treatment regimen costs from more than $80,000 to only $100 in some resource‐limited countries, such as Egypt
 <xref rid="hep41310-bib-0018" ref-type="ref">18</xref>, 
 <xref rid="hep41310-bib-0019" ref-type="ref">19</xref> and Pakistan,
 <xref rid="hep41310-bib-0020" ref-type="ref">20</xref>, 
 <xref rid="hep41310-bib-0021" ref-type="ref">21</xref> availability and accessibility of effective treatment have been rendered surmountable challenges. Nonetheless, diagnosis of those infected has become a global challenge to address this disease burden and to control transmission.
</p>
